We are live on ! Find out more
REVBW icon

Revelation Biosciences Warrant
REVBW

13 hedge funds and large institutions have $9.99K invested in Revelation Biosciences Warrant in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more capital invested

Capital invested by funds: $6.66K → $9.99K (+$3.33K)

18% more funds holding

Funds holding: 1113 (+2)

83% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 6

Holders
13
Holders Change
+2
Holders Change %
+18.18%
% of All Funds
0.16%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
1
Reduced
6
Closed
Calls
Puts
Net Calls
Net Calls Change

REVBW Hedge Fund Activity: Q2 2026 in Review

13 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Revelation Biosciences Warrant (REVBW) for Q2 2026, worth a combined $9.99K — up 50% from $6.66K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new REVBW positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 6 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $525. The largest seller was Soltis Investment Advisors, cutting an estimated $260.

  • 13 institutional investors held Revelation Biosciences Warrant (REVBW) as of Q2 2026, up from 11 in Q1 2026.
  • Funds reported $9.99K of Revelation Biosciences Warrant stock for Q2 2026, up 50% quarter-over-quarter.
  • 2 funds opened new Revelation Biosciences Warrant positions in Q2 2026 and 0 closed out, a net change of +2 holders.
  • The largest Revelation Biosciences Warrant buyer in Q2 2026 was Virtu Financial, an estimated $525 added.
  • The largest Revelation Biosciences Warrant seller in Q2 2026 was Soltis Investment Advisors, an estimated $260 sold.

Based on aggregated 13F filings for Q2 2026.